Ariad Pharmaceuticals (ARIA -12.3%) dives after an abstract from the American Society of...

|By:, SA News Editor

Ariad Pharmaceuticals (ARIA -12.3%) dives after an abstract from the American Society of Hematology indicates 17% of chronic myeloid lukemia patients using Ariad's Ponatinib drug experienced serious side effects, and 15% of patients stopped using the drug.